• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing
  3. / Stocks

Eli Lilly's Conservative Pricing Offers Protection From Political Pressure

Eli Lilly's self-policing on drug pricing protects it from the most prominent political pushbacks.
By KEVIN CURRAN Nov 06, 2018 | 03:15 PM EST
Stocks quotes in this article: LLY, PFE

Eli Lilly and Co. (LLY) is better off than many other drug makers ahead of contentious midterms that could provoke ramped-up regulation.

The company touted its volume-driven earnings beat on Tuesday, noting that it chose not to spike drug prices despite the possible balance sheet benefit.

"Pricing was a bit of a drag this quarter," CEO David Ricks told CNBC. "Of course if we had raised prices it could have offset some of that."

The conservative pricing approach comes as the Trump administration and many liberal candidates favor regulation and transparency in drug pricing, a rare point of agreement.

In the past, "gag clauses" kept pharmacists from telling patients when paying for prescriptions out-of-pocket would cost less than using their insurance.

Ending gag clauses is the latest step in President Trump's blueprint to stop unfair drug pricing. https://t.co/BFxNwoFjoT

— The White House (@WhiteHouse) October 14, 2018

There's no reason patients in Milan, Missouri should be paying more for their medicines than patients in Milan, Italy.

Read more about the latest in Claire's drug pricing investigation from @columbiatribune: https://t.co/rU40lOQNug

— McCaskill Office (@McCaskillOffice) November 1, 2018

Health and Human Services secretary Alex Azar has been vocal in his denouncement of price gouging in the industry.

"Our vision for a new, more transparent drug-pricing system does not rely on voluntary action." Azar said in a statement. "The drug industry remains resistant to providing real transparency around their prices, including the sky-high list prices that many patients pay."

Ricks acknowledged that there is room to work with regulators, as its pricing progression suggests it is willing to do.

"There are some things we like, where we could work with the administration to support free market principles and innovation," he said, advocating for a hands-off approach.

Though he quickly repudiated pricing controls and heavy handed interventionism as an inhibition to innovation.

"There are some things we don't like, importing price controls from Europe is high on that list," Ricks said.

Certainly, Ricks will not be the only industry voice to raise concerns on the import of such harsh regulation should a potentially "bluer" legislature look to work with Trump on a common interest.

Pfizer (PFE) CEO Ian Read touched on the topic extensively in an earnings call on October 30. He suggested that the hot topic will die down in due time.

"I expect that like most industries, we will look at our pricing situation in January and take decisions based on what the competitive set is and what our value proposition is in the new marketplace," he said. "We've been working with the President on parts of the blueprint and I expect our approach by the end of year will be, what I would characterize as business as normal."

Business as normal in 2017 meant price increases charting at about 20% across 91 drugs, per the Financial Times. Such increases would likely draw more than simply angry tweets from the oval office and ire from legislators campaigning on the issue.

The reining in of prices might well pinch margins for many of major pharmaceutical companies, but it might be necessary to maintain industry autonomy and ultimately provide enough profit to invest in R&D.

The bright spot for Eli Lilly investors is that the company seems efficient at policing itself already.

The drug-maker has proven itself capable of besting estimates and ramping research spend even without pumping up prices, an important ability amid possible price crackdowns.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

Employees of TheStreet are restricted from trading individual securities.

TAGS: Earnings | Investing | Stocks | United States

More from Stocks

These Three Small-Cap Stocks Boast Big Dividends

Bob Ciura
May 18, 2022 3:00 PM EDT

Look beyond the mega-cap names for income investing to the more inclusive -- and often smaller -- Dividend Champions.

Can Nvidia Make a Rebound Rally Ahead of Earnings?

Bruce Kamich
May 18, 2022 2:32 PM EDT

Here's what I'd look for NVDA to do in the days ahead.

After Cisco Reports, Will There Be a Tradable Rally?

Bruce Kamich
May 18, 2022 12:04 PM EDT

Let's see how the charts look before earnings Wednesday night.

ServiceNow Picks Up a New Bull on Their Shares

Bruce Kamich
May 18, 2022 11:20 AM EDT

Here's what aggressive traders could do now.

How This Bear Market Is Evolving

James "Rev Shark" DePorre
May 18, 2022 11:13 AM EDT

The recovery from this action is likely to be very uneven.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 01:44 PM EDT STEPHEN GUILFOYLE

    Stocks Under $10 Portfolio

    We're making a series of trades here.
  • 03:07 PM EDT PAUL PRICE

    Why Is Walmart Down Big Today?

    Besides its poor earnings report Walmart was way...
  • 07:14 PM EDT PAUL PRICE

    A New, Very Scary Movie

  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2022 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login